Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmaterials

Full company profile

uuid003c2yn

Namestring
Pharmaterials
Legal namestring
Quotient Sciences
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Pharmaterials is a contract development and manufacturing organization (CDMO) headquartered in Reading, United Kingdom, founded in 2000 and operating with 51-100 employees. The firm's website is pharmaterials.co.uk. Based on the firmographic record, Pharmaterials occupies the small-cap segment of the UK pharmaceutical services market, offering formulation development, clinical manufacturing, and related drug product services to pharmaceutical and biotech clients across the development lifecycle.

The supporting structured intelligence in this dataset, however, is principally attributed to Quotient Sciences — a Nottingham-area CRDMO (Contract Research, Development and Manufacturing Organization) operating across the UK and US, with a service portfolio covering Drug Product Development & Manufacturing, Early Clinical Development (first-in-human and clinical pharmacology), Translational Pharmaceutics® integrated drug development, and Pediatric Formulation Development. Quotient Sciences markets itself as a CRDMO with a registered trademark in Translational Pharmaceutics® and a direct enterprise sales motion targeting pharma and biotech accounts. Whether Pharmaterials and Quotient Sciences are the same operating entity under different trading names, related entities, or distinct firms whose data has been conflated in the source scrape is not resolved by the available evidence. This analysis treats Pharmaterials strictly on the basis of its confirmed firmographic record and flags the data provenance issue as a material limitation.

On the firmographic record alone, Pharmaterials is positioned as a long-tenured, sub-100-employee UK CDMO serving pharmaceutical and biotech customers with development and manufacturing services, with no disclosed revenue, funding, ownership, or leadership data available in the source material.

Short descriptiontext

Pharmaterials is a Reading, UK-based contract development and manufacturing organization (CDMO) founded in 2000, employing 51-100 staff to deliver formulation development and pharmaceutical manufacturing services to pharma and biotech clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersReading, United Kingdom
HQ citystring
Reading
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical drug development, contract manufacturing services, formulation development, clinical pharmacology trials, commercial drug manufacturing
Industry4 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Development and Manufacturing Services (CDMO/CRDMO)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research and Development Services
TypeProfessional Services
Description

Service-based revenue model providing integrated pharmaceutical development services including formulation development, clinical manufacturing, and early clinical development programs. Revenue is generated through project-based contracts with pharmaceutical and biotech companies across various development stages.

quotientsciences.com
2Drug Product Manufacturing
TypeManaged Services
Description

cGMP manufacturing services for clinical trial materials and commercial drug product supply, generating recurring revenue from ongoing manufacturing relationships with clients.

quotientsciences.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Translational Pharmaceutics
Description

The company's unique approach to drug development, integrating clinical activities with real-time cGMP drug product manufacturing

quotientsciences.com
Core offering1 text field

Pharmaterials is a pharmaceutical contract development and manufacturing organization (CDMO/CRDMO) providing integrated drug development and manufacturing services to pharmaceutical and biotech companies. The company offers formulation development, cGMP clinical and commercial drug product manufacturing, early clinical development programs (including first-in-human and Phase 1 clinical pharmacology), the proprietary Translational Pharmaceutics® approach, and pediatric formulation development, taking client molecules from candidate selection through to commercial drug supply.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Quotient Sciences operates as a pharmaceutical CRDMO (Contract Research, Development and Manufacturing Organization) offering an integrated portfolio of drug development services. The company provides four core service offerings: Drug Product Development & Manufacturing (covering formulation development, clinical manufacturing, and commercial production), Early Clinical Development (first-in-human and clinical pharmacology programs), Translational Pharmaceutics® Integrated Drug Development (which uniquely combines clinical activities with real-time cGMP manufacturing), and Pediatric Formulation Development. These services are designed to take molecules from candidate selection through first-in-human clinical testing to commercial supply, with an emphasis on accelerating timelines.

Product and service4 records
1Drug Product Development & Manufacturing
CategoryPharmaceutical Contract Development and Manufacturing
Description

Experienced formulation development, clinical manufacturing, and sustained commercial production of pharmaceutical products, delivered to pharmaceutical and biotech companies developing small molecule drugs.

2Early Clinical Development
CategoryClinical Research Services
Description

Integrated first-in-human and clinical pharmacology programs designed to help pharmaceutical and biotech companies make critical go/no-go decisions earlier in drug development; includes Phase I clinical pharmacology, regulatory, and labeling studies.

3Translational Pharmaceutics® Integrated Drug Development
CategoryProprietary Drug Development Methodology
Description

Unique, proprietary approach to drug development that integrates clinical activities with real-time cGMP drug product manufacturing, enabling adaptive clinical program decisions and accelerated development timelines for pharmaceutical and biotech clients.

4Pediatric Formulation Development
CategoryPharmaceutical Formulation Services
Description

Specialized solutions for developing age-appropriate drug formulations for pediatric populations, serving pharmaceutical and biotech companies needing tailored pediatric dosage forms.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Recipharm
TypeBroad incumbent
Description

European-headquartered CDMO offering formulation development, clinical and commercial manufacturing across multiple dosage forms. Comparable as a mid-to-large CDMO serving pharma sponsors across the small-molecule development lifecycle.

TypeDirect peer
Description

Parent/affiliated CRDMO with operations in the UK and US that pioneered Translational Pharmaceutics®. Directly comparable as a small-molecule drug product CDMO offering formulation, clinical manufacturing, and integrated development services to pharma and biotech sponsors.

TypeBroad incumbent
Description

Global CDMO offering clinical trial material manufacturing, commercial supply, and formulation development. Comparable in providing GMP manufacturing and clinical supply services to pharma sponsors.

TypeBroad incumbent
Description

European CDMO offering solid dose, semi-solid, and sterile manufacturing plus formulation development. Comparable to Pharmaterials as a CDMO providing small-molecule drug product development and clinical supply services.

TypeEmerging player
Description

India-headquartered CDMO providing drug substance, drug product, and formulation development services. Comparable as a mid-sized emerging CDMO competing in the small-molecule development and manufacturing space.

6APC (Ardena)
TypeDirect peer
Description

European CDMO offering small-molecule drug substance, drug product, and formulation development including GMP clinical manufacturing. Highly comparable as a mid-sized specialist focused on small-molecule CDMO services.

TypeBroad incumbent
Description

Small-molecule API and drug product CDMO offering formulation development, clinical and commercial manufacturing. Directly comparable in the small-molecule CDMO space with overlapping service portfolio targeting pharma and biotech sponsors.

TypeBroad incumbent
Description

Global CDMO providing drug substance and drug product services including formulation development and clinical manufacturing. Comparable as a contract development and manufacturing partner for small-molecule programs.

TypeDirect peer
Description

Swiss-based specialty CDMO focused on hazardous small-molecule API and drug product development. Comparable as a mid-sized specialist CDMO offering formulation and GMP manufacturing for pharma sponsors.

TypeBroad incumbent
Description

Global CDMO offering API, drug product, and formulation development plus clinical and commercial manufacturing. Comparable as a broad CDMO serving pharma and biotech across the development lifecycle.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmaterials

Pharmaceutical Contract Development and Manufacturing Services (CDMO/CRDMO)pharmaterials.co.uk

Pharmaterials is a Reading, UK-based contract development and manufacturing organization (CDMO) founded in 2000, employing 51-100 staff to deliver formulation development and pharmaceutical manufacturing services to pharma and biotech clients.

What Pharmaterials does

Pharmaterials is a contract development and manufacturing organization (CDMO) headquartered in Reading, United Kingdom, founded in 2000 and operating with 51-100 employees. The firm's website is pharmaterials.co.uk. Based on the firmographic record, Pharmaterials occupies the small-cap segment of the UK pharmaceutical services market, offering formulation development, clinical manufacturing, and related drug product services to pharmaceutical and biotech clients across the development lifecycle.

The supporting structured intelligence in this dataset, however, is principally attributed to Quotient Sciences — a Nottingham-area CRDMO (Contract Research, Development and Manufacturing Organization) operating across the UK and US, with a service portfolio covering Drug Product Development & Manufacturing, Early Clinical Development (first-in-human and clinical pharmacology), Translational Pharmaceutics® integrated drug development, and Pediatric Formulation Development. Quotient Sciences markets itself as a CRDMO with a registered trademark in Translational Pharmaceutics® and a direct enterprise sales motion targeting pharma and biotech accounts. Whether Pharmaterials and Quotient Sciences are the same operating entity under different trading names, related entities, or distinct firms whose data has been conflated in the source scrape is not resolved by the available evidence. This analysis treats Pharmaterials strictly on the basis of its confirmed firmographic record and flags the data provenance issue as a material limitation.

On the firmographic record alone, Pharmaterials is positioned as a long-tenured, sub-100-employee UK CDMO serving pharmaceutical and biotech customers with development and manufacturing services, with no disclosed revenue, funding, ownership, or leadership data available in the source material.

Pharmaterials firmographics

Firmographics
Name
Pharmaterials
Legal name
Quotient Sciences
Website
https://pharmaterials.co.uk
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
51–100 employees
Short description
Pharmaterials is a Reading, UK-based contract development and manufacturing organization (CDMO) founded in 2000, employing 51-100 staff to deliver formulation development and pharmaceutical manufacturing services to pharma and biotech clients.
Ownership category
akta.pro rank

Pharmaterials industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing Services (CDMO/CRDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical drug development
  • Contract manufacturing services
  • Formulation development
  • Clinical pharmacology trials
  • Commercial drug manufacturing

Where Pharmaterials is headquartered

Location

Headquarters

HQ city
Reading
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Pharmaterials business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Research and Development Services: Service-based revenue model providing integrated pharmaceutical development services including formulation development, clinical manufacturing, and early clinical development programs. Revenue is generated through project-based contracts with pharmaceutical and biotech companies across various development stages.
  2. Drug Product Manufacturing: cGMP manufacturing services for clinical trial materials and commercial drug product supply, generating recurring revenue from ongoing manufacturing relationships with clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Pharmaterials product offering

Product offering

Core offering

Pharmaterials is a pharmaceutical contract development and manufacturing organization (CDMO/CRDMO) providing integrated drug development and manufacturing services to pharmaceutical and biotech companies. The company offers formulation development, cGMP clinical and commercial drug product manufacturing, early clinical development programs (including first-in-human and Phase 1 clinical pharmacology), the proprietary Translational Pharmaceutics® approach, and pediatric formulation development, taking client molecules from candidate selection through to commercial drug supply.

Product overview

Quotient Sciences operates as a pharmaceutical CRDMO (Contract Research, Development and Manufacturing Organization) offering an integrated portfolio of drug development services. The company provides four core service offerings: Drug Product Development & Manufacturing (covering formulation development, clinical manufacturing, and commercial production), Early Clinical Development (first-in-human and clinical pharmacology programs), Translational Pharmaceutics® Integrated Drug Development (which uniquely combines clinical activities with real-time cGMP manufacturing), and Pediatric Formulation Development. These services are designed to take molecules from candidate selection through first-in-human clinical testing to commercial supply, with an emphasis on accelerating timelines.

Differentiator

Problem solved

Functional benefit

Brands

  • Translational Pharmaceutics: The company's unique approach to drug development, integrating clinical activities with real-time cGMP drug product manufacturing

Products and services

  • Drug Product Development & Manufacturing Experienced formulation development, clinical manufacturing, and sustained commercial production of pharmaceutical products, delivered to pharmaceutical and biotech companies developing small molecule drugs.
  • Early Clinical Development Integrated first-in-human and clinical pharmacology programs designed to help pharmaceutical and biotech companies make critical go/no-go decisions earlier in drug development; includes Phase I clinical pharmacology, regulatory, and labeling studies.
  • Translational Pharmaceutics® Integrated Drug Development Unique, proprietary approach to drug development that integrates clinical activities with real-time cGMP drug product manufacturing, enabling adaptive clinical program decisions and accelerated development timelines for pharmaceutical and biotech clients.
  • Pediatric Formulation Development Specialized solutions for developing age-appropriate drug formulations for pediatric populations, serving pharmaceutical and biotech companies needing tailored pediatric dosage forms.

Companies that use Pharmaterials

Customer profile

Segments1 record

Ideal customer profiles1 record

Pharmaterials technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Pharmaterials partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves2 records

Expansion highlights2 records

Pharmaterials competitors and assessment

Company assessment

Broad incumbents

  • Recipharm: European-headquartered CDMO offering formulation development, clinical and commercial manufacturing across multiple dosage forms. Comparable as a mid-to-large CDMO serving pharma sponsors across the small-molecule development lifecycle.
  • PCI Pharma Services: Global CDMO offering clinical trial material manufacturing, commercial supply, and formulation development. Comparable in providing GMP manufacturing and clinical supply services to pharma sponsors.
  • Aenova Group: European CDMO offering solid dose, semi-solid, and sterile manufacturing plus formulation development. Comparable to Pharmaterials as a CDMO providing small-molecule drug product development and clinical supply services.
  • Cambrex: Small-molecule API and drug product CDMO offering formulation development, clinical and commercial manufacturing. Directly comparable in the small-molecule CDMO space with overlapping service portfolio targeting pharma and biotech sponsors.
  • Piramal Pharma Solutions: Global CDMO providing drug substance and drug product services including formulation development and clinical manufacturing. Comparable as a contract development and manufacturing partner for small-molecule programs.
  • AMRI (Curia): Global CDMO offering API, drug product, and formulation development plus clinical and commercial manufacturing. Comparable as a broad CDMO serving pharma and biotech across the development lifecycle.

Direct peers

  • Quotient Sciences: Parent/affiliated CRDMO with operations in the UK and US that pioneered Translational Pharmaceutics®. Directly comparable as a small-molecule drug product CDMO offering formulation, clinical manufacturing, and integrated development services to pharma and biotech sponsors.
  • APC (Ardena): European CDMO offering small-molecule drug substance, drug product, and formulation development including GMP clinical manufacturing. Highly comparable as a mid-sized specialist focused on small-molecule CDMO services.
  • Dottikon ES: Swiss-based specialty CDMO focused on hazardous small-molecule API and drug product development. Comparable as a mid-sized specialist CDMO offering formulation and GMP manufacturing for pharma sponsors.

Emerging players

  • Sai Life Sciences: India-headquartered CDMO providing drug substance, drug product, and formulation development services. Comparable as a mid-sized emerging CDMO competing in the small-molecule development and manufacturing space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Pharmaterials financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmaterials leadership team

Management profile

Number of profiles

Pharmaterials funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmaterials M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaterials

What does Pharmaterials do?

Pharmaterials is a pharmaceutical contract development and manufacturing organization (CDMO/CRDMO) providing integrated drug development and manufacturing services to pharmaceutical and biotech companies. The company offers formulation development, cGMP clinical and commercial drug product manufacturing, early clinical development programs (including first-in-human and Phase 1 clinical pharmacology), the proprietary Translational Pharmaceutics® approach, and pediatric formulation development, taking client molecules from candidate selection through to commercial drug supply.

Is Pharmaterials a public or private company?

Pharmaterials is a private company. It is classified as unknown and is currently operating.

When was Pharmaterials founded?

Pharmaterials was founded in 2000. It employs 51 to 100 people.

Where is Pharmaterials based?

Pharmaterials is headquartered in Reading, United Kingdom, in the Europe region.

How does Pharmaterials make money?

Two revenue lines are on record. Contract Research and Development Services are the primary driver. The others are drug Product Manufacturing.

Who are Pharmaterials's main competitors?

Broad incumbents on record are Recipharm, PCI Pharma Services, Aenova Group, Cambrex, Piramal Pharma Solutions and AMRI (Curia). Direct peers are Quotient Sciences, APC (Ardena) and Dottikon ES. Sai Life Sciences is listed as an emerging player.

Does Pharmaterials have an API?

No public API is recorded for Pharmaterials.

What industry is Pharmaterials in?

Pharmaterials's product category is Pharmaceutical Contract Development and Manufacturing Services (CDMO/CRDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales